Smithkline Beecham Corporation

Nektar Therapeutics

Sarma Duddu

Nageswara R Palepu

Gopadi M Venkatesh

Thomas E Tarara

David Lechuga-Ballesteros

Sarvajna Kumar Dwivedi

Danforth Miller

Michael A Eldon

Keith Washco

Richard Malcolmson

Trixie Tan

Alan Kugler

Theresa D Sweeney

Srinivas Palakodaty

Christopher Frantz

A composition includes particles including at least about 95 wt % of amphotericin B, wherein the particles have a mass median diameter ranging from about 1.1 &#x3bc;m to about 1.9 &#x3bc;m. Another composition also includes particles including at least about 95 wt % of amphotericin B, wherein at least about 80 wt % of the particles have a geometric diameter ranging from about 1.1 &#x3bc;m to about 1.9 &#x3bc;m. Yet another composition includes particles including amphotericin B, wherein the particles have a mass median diameter less than about 1.9 &#x3bc;m, and wherein the amphotericin B has a crystallinity level of at least about 20%. Unit dosage forms, delivery systems, and methods may involve similar compositions.

Compositions comprising amphotericin B, methods, and systems

The invention relates to (E)-&agr;-&lsqb;2-n-butyl-1-&lsqb;(4-carboxyphenyl)methyl&rsqb;-1-H-imidazol-5-yl&rsqb;methylene-2-thiopheneproprionic acid monomethanesulfonate dihydrate, a process for its production, compositions containing the compound and methods of using the compound to block angiotensin II receptors and to treat hypertension, congestive heart failure and renal failure.

Eprosartan dihydate and a process for its production and formulation

This invention relates to (E)-&agr;-&lsqb;2-n-butyl-1-&lsqb;(4-carboxyphenyl)methyl&rsqb;-1) H-imidazol-5-yl&rsqb;methylene-2-thiophenepropionic acid monomethanfesulfonate monohydrate, compositions containing the compound and methods of using the compound to block angiotensin II receptors and to treat hypertension, congestive heart failure and renal failure.

Eprosartan monohydrate

Growing community of inventors

Redwood City, CA, United States of America

Sarma Duddu